Abstract: SA-PO0579
Three-Month Interim Analysis of Ketogenic Metabolic Therapy in Japanese Patients with ADPKD
Session Information
- Cystic Kidney Diseases: Clinical Research
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases
Authors
- Kawano, Haruna, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo, Tokyo, Japan
- Koizumi, Wakana, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo, Tokyo, Japan
- Lu, Yan, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo, Tokyo, Japan
- Kimura, Tomoki, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo, Tokyo, Japan
- Ikehata, Yoshihiro, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo, Tokyo, Japan
- Muto, Satoru, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo, Tokyo, Japan
- Kuo, Chien-Yung, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo, Tokyo, Japan
- Muensterman, Emily Grace, Santa Barbara Nutrients, Inc,, Santa Barbara, California, United States
- Anonuevo, Clarissa susan, Kidney Nutrition Institute, Titusville, Florida, United States
- Welsh, Kelly L., Kidney Nutrition Institute, Titusville, Florida, United States
- Saville, Jessianna, Kidney Nutrition Institute, Titusville, Florida, United States
- Weimbs, Thomas, University of California Santa Barbara, Santa Barbara, California, United States
- Horie, Shigeo, Juntendo Daigaku Igakubu Daigakuin Igaku Kenkyuka, Bunkyo, Tokyo, Japan
Background
Recent studies have identified metabolic abnormalities as a key pathological feature of ADPKD and ketogenic metabolic therapy using ketogenic diets has gained significant attention. We are currently conducting the first clinical study to evaluate the efficacy and tolerability of a ketogenic diet supported by beta-hydroxybutyrate (BHB) and citrate supplementation in Asian patients. This report presents our preliminary findings after a three-month intervention period.
Methods
This study enrolled adult ADPKD patients who had not previously received tolvaptan treatment. Participants followed our ketogenic diet program. Unlike conventional ketogenic diets, this protocol also emphasizes a reduction in the lithogenic risk and incorporates KetoCitra®, a medical food containing BHB and alkaline citrate, which is intended to augment the ketogenic diet’s effects while minimizing potential side effects. The control group maintained their regular diet. Kidney volume and blood parameters were assessed at baseline and after three months for comparative analysis.
Results
A total of 23 participants in the intervention group and 7 in the control group were evaluated for this interim analysis. The mean age at baseline was 47.3 years and 45.7 years, while the mean BMI was 22.41 and 22.01, respectively. Baseline median estimated glomerular filtration rate (eGFR) and total kidney volume (TKV) were 58.3 ml/min/1.73 m2 and 999.9 ml in the intervention group, and 60.5 ml/min/1.73 m2 and 670.7 ml in the control group. After three months, the intervention group experienced significantly greater weight loss compared to the control group (mean change: -4.32 kg vs. -0.87 kg; p〈0.001). The change in TKV was also statistically significant in the intervention group (-5.01% vs. +8.03%;p〈0.05). No significant difference was observed in eGFR change between the groups (0.59 vs. -1.57 ml/min/1.73 m2; p=0.0651). Tolerability was high, no participants discontinued or interrupted the ketogenic diet during the three-month study period.
Conclusion
Although these are preliminary results, our findings indicate that even among Japanese ADPKD patients the intervention was well tolerated and may offer therapeutic benefits, particularly in reducing kidney volume.